MintNeuro and Motif Neurotech collaborate for mental health therapies
MintNeuro has signed a partnership with Motif Neurotech to advance the development of miniature brain-computer interface (BCI) therapy for mental…
01 May 2026
Merck KGaA doses first patient in Phase III programme of enpatoran
Merck KGaA (Merck) has dosed the first patient in its Phase III clinical programme, ELOWEN-1 and ELOWEN-2, evaluating the oral therapy enpatoran in individuals with lupus who have active skin…
01 May 2026
LEO Pharma to acquire gene therapy company Replay
LEO Pharma has signed a definitive agreement for the acquisition of Replay, a gene therapy company that develops treatments for rare genetic dermatological conditions. The acquisition aims to strengthen LEO…
30 Apr 2026
Ray Therapeutics receives EMA PRIME status for gene therapy
Ray Therapeutics has received priority medicines (PRIME) designation from the European Medicines Agency (EMA) for its RTx-015 gene therapy to treat retinitis pigmentosa (RP). The designation recognises the potential of…
30 Apr 2026
enVVeno Medical secures FDA IDE approval for venous valve study
enVVeno Medical has received the investigational device exemption (IDE) approval from the US Food and Drug Administration (FDA) for a pivotal study involving a non-surgical replacement venous valve. The approval…
30 Apr 2026
Precision begins patient enrolment for FUNCTION-DMD trial
Precision BioSciences has activated Arkansas Children’s Hospital as the first site and initiated patient enrolment for its Phase I/II FUNCTION-DMD clinical trial of PBGENE-DMD for Duchenne muscular dystrophy (DMD). PBGENE-DMD…
29 Apr 2026
Abbott secures FDA approval for Ultreon 3.0 imaging platform
Abbott has received the US Food and Drug Administration (FDA) approval and CE Mark for its Ultreon 3.0 AI-powered coronary imaging platform. The approval enables the integration of automated imaging…